FDA warned North American Hirudin Biotech Products that Hirudin and Red 65 are unapproved drugs sold with disease-treatment claims.
What happened
FDA reviewed http://ushirudin.com/ in February and April 2021, plus linked websites http://www.naturalhirudin.com/ and http://buyred65.com/, and found the company takes orders there for Hirudin and Red 65. The websites claimed the products thin blood, lower cholesterol, treat cardiovascular disease, and serve as alternatives to heparin, so FDA treated them as drugs. FDA said they are not generally recognized as safe and effective for those uses and lack adequate directions for use.
What FDA found
The website claims make Hirudin and Red 65 drugs under the law because they are intended to cure, mitigate, treat, or prevent disease.
section 201(g)(1)(B) [21 U.S.C. § 321(g)(1)(B)]Hirudin and Red 65 are unapproved new drugs (products that need FDA approval before sale) because they are intended to treat disease but are not generally recognized as safe and effective for those uses.
section 201(p) [21 U.S.C. § 321(p)]; sections 301(d) and 505(a) [21 U.S.C. § 331(d) and § 355(a)]The products are misbranded (labeled without adequate directions) because they fail to bear adequate directions for their intended uses.
section 502(f)(1) [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5The products are intended for diseases that a layperson cannot safely diagnose or treat without a licensed practitioner, so adequate directions for safe lay use cannot be written.
section 502(f)(1) [21 U.S.C. § 352(f)(1)]Introducing or delivering the misbranded drugs into interstate commerce violates the Act.
section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA asks the company to notify it in writing within 15 working days of receipt of the letter about specific steps taken to address the violations, including an explanation and related documentation; if corrective actions cannot be completed in that time, the company must state why and when it will finish.
Who should pay attention
- online sellers of herbal or supplement products that make disease claims
- clinicians and patients managing anticoagulant therapy
- distributors or marketplaces offering hirudin-containing products
This is a summary. Read the original letter on fda.gov.